Nobivac Parvo C (10 dose)

Target species Dogs. Indications for use For active immunisation of dogs to prevent mortality, clinical signs and viral excretion following canine parvovirus infection. Specific claims: Onset of immunity: 1 week Duration of immunity: at least three years. Contraindications Do not use in unhealthy animals. The vaccine may not be effective in dogs incubating the disease at the time of vaccination. Some animals may be immunologically incompetent and fail to respond to vaccination. Animals that have received the corresponding anti-serum or immunosuppressive drugs should not be vaccinated until an interval of at least 4 weeks has elapsed. Special warnings for each target species The efficacy of the CPV component of the vaccine may be reduced due to maternal antibody interference. However, the vaccine has been proved to be of benefit against virulent challenge in the presence of maternal antibody levels to CPV that are likely to be encountered under field conditions. Special precautions for use Only healthy dogs should be vaccinated. The canine parvovirus vaccine strain may be shed at very low levels for up to 8 days after inoculation. However there is no evidence of any reversion to virulence of the vaccine strain and therefore no need to separate unvaccinated dogs from contact with recently vaccinated individuals. Operator warnings None. Adverse Reactions A diffuse swelling, up to 5 mm in diameter, may be observed at the site of injection. Occasionally this swelling may be hard and painful and last for up to 3 days post injection. In the rare event of a hypersensitivity reaction occurring following vaccination, administer an antihistamine, corticosteroid or adrenaline, without delay and by the most immediate route. Use during pregnancy or lactation Can be used in pregnant bitches which have previously been vaccinated with the CPV (strain 154) antigens included in the Nobivac vaccine series. Interactions Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccines of the Nobivac series for subcutaneous administration against canine leptospirosis caused by all or some of the following serovars: L. interrogans serogroup Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri serogroup Grippotyphosa serovar Bananal/Liangguang. After administration with one of the leptospirosis vaccines, a mild and transient increase in body temperature (≤ 1 °C) may occur for a few days after vaccination, with some pups showing less activity and/or a reduced appetite. A small transient swelling (≤ 4 cm), which can occasionally be firm and painful on palpation, may be observed at the site of injection. Any such swelling will either have disappeared or be clearly diminished by 14 days post-vaccination. After mixed administration of an overdose of Nobivac Parvo-C and an overdose of the leptospirosis vaccines of the Nobivac series, transient local reactions such as diffuse to firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no longer than 5 weeks, however some may take a little longer to completely disappear. Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with the inactivated vaccine of the Nobivac series against rabies. After administration with the rabies vaccine, where this product is authorised, transient local reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post dosing. Consult product leaflets before administering products simultaneously. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Vat Rate: 20%